Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE:SVA) and the University of Alberta today announced the treatment of the first patient with insulin-producing islets transplanted into Sernova's Cell Pouch? in a Phase I/II clinical study to treat Type-1 diabetes led by Dr. James Shapiro, Professor of Surgery and Medicine, University of Alberta and Director, Clinical Islet Transplant Program. Sernova will host a conference call at 9 a.m. EDT, today, Aug. 16, 2012, to discuss the company's clinical and business developments.
"The Sernova Cell Pouch? implantation and transplantation processes are simple, rapid minimally invasive procedures, conducted on an outpatient basis under local anesthesia," said Dr. Shapiro. "This offers substantial potential benefit over the Edmonton protocol and the ease of use provides an opportunity for the Cell Pouch? to become the standard of care for people with diabetes if it proves to be effective in these initial trials."
http://www.stockhouse.com/News/CanadianReleasesDetail.aspx?n=8591692
"The Sernova Cell Pouch? implantation and transplantation processes are simple, rapid minimally invasive procedures, conducted on an outpatient basis under local anesthesia," said Dr. Shapiro. "This offers substantial potential benefit over the Edmonton protocol and the ease of use provides an opportunity for the Cell Pouch? to become the standard of care for people with diabetes if it proves to be effective in these initial trials."
http://www.stockhouse.com/News/CanadianReleasesDetail.aspx?n=8591692